LT3002298T - Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai - Google Patents

Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai

Info

Publication number: LT3002298T
Authority: LT; Lithuania
Prior art keywords: factor; methods; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2007-11-21

Application number

LT15189714T

Other languages

English (en)

Inventor

Andras Gruber

Erik Tucker

Stephen Hanson

David Gailani

Original Assignee

Univ Oregon Health & Science

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-21

Filing date

2008-11-21

Publication date

2019-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3002298(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-21 Application filed by Univ Oregon Health & Science, Univ Vanderbilt filed Critical Univ Oregon Health & Science

2019-12-10 Publication of LT3002298T publication Critical patent/LT3002298T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LT15189714T 2007-11-21 2008-11-21 Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai LT3002298T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US98952307P	2007-11-21	2007-11-21

Publications (1)

Publication Number	Publication Date
LT3002298T true LT3002298T (lt)	2019-12-10

Family

ID=40568500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT15189714T LT3002298T (lt)	2007-11-21	2008-11-21	Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai

Country Status (15)

Country	Link
US (7)	US8236316B2 (lt)
EP (2)	EP2222707B1 (lt)
JP (1)	JP2011504371A (lt)
AU (1)	AU2008326348B2 (lt)
CA (1)	CA2705851C (lt)
CY (1)	CY1122270T1 (lt)
DK (2)	DK3002298T3 (lt)
ES (2)	ES2755376T3 (lt)
HR (1)	HRP20191999T1 (lt)
HU (1)	HUE046564T2 (lt)
LT (1)	LT3002298T (lt)
PL (1)	PL3002298T3 (lt)
PT (1)	PT3002298T (lt)
SI (1)	SI3002298T1 (lt)
WO (1)	WO2009067660A2 (lt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3002298T (lt) *	2007-11-21	2019-12-10	Univ Oregon Health & Science	Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
HRP20181727T1 (hr) *	2008-06-19	2019-02-08	Prothix Bv	Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
DK2379084T3 (en)	2008-10-15	2018-01-22	Ionis Pharmaceuticals Inc	MODULATION OF FACTOR 11 EXPRESSION
TR201904662T4 (tr) *	2008-12-18	2019-05-21	Gruber Andras	Anti-fxı antikorları ve kullanma yöntemleri.
AU2010236286B2 (en) *	2009-04-15	2013-06-06	Isis Pharmaceuticals, Inc.	Modulation of inflammatory responses by Factor XI
SI2542257T1 (en) *	2010-03-01	2018-01-31	Bayer Healthcare Llc	Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
ES2646191T3 (es) *	2011-03-09	2017-12-12	Csl Behring Gmbh	Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CA2872926C (en) *	2012-05-10	2022-07-05	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014089493A1 (en)	2012-12-07	2014-06-12	Vanderbilt University	Antibodies against factor xii and uses thereof
AU2014212194A1 (en) *	2013-02-01	2015-09-17	Becton, Dickinson And Company	Blood collection devices containing contact pathway inhibition additives
ES2844189T3 (es)	2013-03-08	2021-07-21	Csl Behring Gmbh	Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
AP2017009721A0 (en)	2014-08-07	2017-01-31	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
EP3194437B1 (en)	2014-08-07	2021-01-20	Novartis AG	Angiopoietin-like 4 (angptl4) antibodies and methods of use
JOP20200312A1 (ar) *	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) *	2015-07-23	2017-01-26	The Regents Of The University Of California	Antibodies to coagulation factor xia and uses thereof
CA3010224A1 (en)	2016-01-22	2017-07-27	Merck Sharp & Dohme Corp.	Anti-coagulation factor xi antibodies
EP3433279A1 (en) *	2016-03-23	2019-01-30	Prothix BV	Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017286432B2 (en) *	2016-06-14	2020-09-24	Adimab, Llc	Anti-coagulation factor XI antibodies
EP3293593B1 (en) *	2016-09-12	2019-03-20	Sandvik Intellectual Property AB	Method for estimating error propagation
ES2984011T3 (es) *	2016-09-20	2024-10-28	Aronora Inc	Nuevos anticuerpos contra el factor XI y usos de los mismos
JP7139332B2 (ja)	2016-12-23	2022-09-20	ノバルティスアーゲー	第ｘｉ因子抗体および使用方法
CN118320078A (zh) *	2016-12-23	2024-07-12	诺华股份有限公司	采用抗因子XI/XIa抗体治疗的方法
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
CN108409863B (zh) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
WO2019102353A1 (en)	2017-11-22	2019-05-31	Novartis Ag	Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US11155638B2 (en)	2018-05-08	2021-10-26	Rhode Island Hospital	Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
CA3098136A1 (en)	2018-05-09	2019-11-14	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing fxi expression
AU2018436195A1 (en) *	2018-08-09	2021-02-18	Shanghai Benemae Pharmaceutical Corporation	Anti-factor XI antibodies
BR112021014313A2 (pt)	2019-01-21	2021-10-05	Aronora Inc.	Anticorpos humanizados inovadores contra o fator xi que tem efeitos anti-trombóticos e anti-inflamatórios e usos dos mesmos
KR20220019806A (ko) *	2019-06-12	2022-02-17	씨에스엘 이노베이션 피티와이 엘티디	가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
WO2022002233A1 (zh) *	2020-07-03	2022-01-06	苏州康宁杰瑞生物科技有限公司	凝血因子xi(fxi)结合蛋白
WO2024141099A1 (zh) *	2022-12-30	2024-07-04	甘李药业股份有限公司	抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1986005807A1 (en)	1985-04-01	1986-10-09	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
AU631802B2 (en)	1988-06-14	1992-12-10	Cetus Oncology Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en)	1990-03-20	1997-09-24	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies with receptor binding ligands in place of their constant region
ES2178635T3 (es)	1990-11-09	2003-01-01	Stephen D Gillies	Inmunoconjugados de citoquinas.
FR2686087A1 (fr)	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en)	1998-08-07	2003-12-25	Feuerstein Giora Z.	Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6623960B1 (en) *	1999-02-12	2003-09-23	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
WO2001087339A1 (en) *	2000-05-15	2001-11-22	Smithkline Beecham Corporation	Antithrombotic agents
JP4368196B2 (ja)	2000-11-17	2009-11-18	ユニバーシティーオブロチェスター	真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
AU2002327164A1 (en)	2001-01-29	2002-12-09	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080138837A1 (en) *	2004-07-19	2008-06-12	Robert Greenfield	Methods and kits for detecting and measuring ADAMTS13/FXI complexes
EP1812062B1 (en) *	2004-10-25	2022-03-09	Merck Sharp & Dohme Corp.	Anti-addl antibodies and uses thereof
US7859456B2 (en)	2006-10-10	2010-12-28	Sirf Technology Holdings, Inc.	Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
MX2009011500A (es) *	2007-04-23	2010-01-29	Schering Corp	Anticuerpos anti-mdl-1.
LT3002298T (lt) *	2007-11-21	2019-12-10	Univ Oregon Health & Science	Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
HRP20181727T1 (hr)	2008-06-19	2019-02-08	Prothix Bv	Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
JP5501369B2 (ja)	2008-11-25	2014-05-21	メルク・シャープ・アンド・ドーム・コーポレーション	可溶性グアニレートシクラーゼ活性化剤
EP2575473B1 (en)	2010-05-27	2016-01-20	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
CA2803688A1 (en)	2010-06-25	2011-12-29	Bayer Intellectual Property Gmbh	Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2708539A1 (de)	2010-07-09	2014-03-19	Bayer Intellectual Property GmbH	Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en)	2011-01-11	2014-06-19	Bayer Pharma Aktiengessellschaft	Substituted imidazopyridines and imidazopyridazines and the use thereof
EP2699578B1 (de)	2011-04-21	2016-04-20	Bayer Intellectual Property GmbH	Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
CA2844730A1 (en)	2011-09-01	2013-03-07	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP6054967B2 (ja)	2011-09-02	2016-12-27	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換アネレート化ピリミジンおよびその使用
CA2872926C (en)	2012-05-10	2022-07-05	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

2008
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/en active
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en not_active Ceased
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown

Also Published As

Publication number	Publication date
SI3002298T1 (sl)	2019-12-31
HK1223114A1 (en)	2017-07-21
AU2008326348A1 (en)	2009-05-28
EP3002298B1 (en)	2019-08-28
PT3002298T (pt)	2019-11-20
PL3002298T3 (pl)	2020-03-31
ES2566963T3 (es)	2016-04-18
WO2009067660A2 (en)	2009-05-28
EP2222707B1 (en)	2016-01-06
EP2222707A2 (en)	2010-09-01
CA2705851C (en)	2016-11-01
US8236316B2 (en)	2012-08-07
US9636399B2 (en)	2017-05-02
US20130171144A1 (en)	2013-07-04
US20150322163A1 (en)	2015-11-12
HUE046564T2 (hu)	2020-03-30
US20140322219A1 (en)	2014-10-30
DK3002298T3 (da)	2019-10-28
EP3002298A1 (en)	2016-04-06
US8399648B2 (en)	2013-03-19
CY1122270T1 (el)	2020-11-25
HRP20191999T1 (hr)	2020-02-07
DK2222707T3 (en)	2016-04-11
US20120276112A1 (en)	2012-11-01
US9125895B2 (en)	2015-09-08
US20180355057A1 (en)	2018-12-13
US10577428B2 (en)	2020-03-03
CA2705851A1 (en)	2009-05-28
US20110020349A1 (en)	2011-01-27
ES2755376T3 (es)	2020-04-22
WO2009067660A3 (en)	2009-07-09
US20170204195A1 (en)	2017-07-20
AU2008326348B2 (en)	2014-01-30
JP2011504371A (ja)	2011-02-10

Publication	Publication Date	Title
HUE046564T2 (hu)	2020-03-30	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
IL266039A (en)	2019-06-30	Anti-factor D antibodies of human origin and their uses
HRP20181969T1 (hr)	2019-02-08	Humanizirana protutijela protiv čimbenika d i njihova upotreba
EP2021029A4 (en)	2010-01-06	HUMANIZED FC RIB SPECIFIC ANTIBODIES AND METHOD FOR THEIR USE
IL200610A0 (en)	2010-05-17	Human monoclonal anti-ip-10 antibodies and uses thereof
PL2594586T3 (pl)	2015-02-27	Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania
IL195573A0 (en)	2011-08-01	Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2347038A4 (en)	2013-06-12	METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
IL248723B (en)	2018-03-29	Specific antibodies against the bcr complex and methods of using them
PT2373691T (pt)	2019-05-08	Anticorpos anti-fxi e métodos de utilização
IL196550A0 (en)	2011-08-01	Anti-il-6 monoclonal antibodies and uses thereof
PT2185719E (pt)	2014-02-20	Anticorpos anti-rantes e processos para a sua utilização
ZA201101651B (en)	2012-06-27	Anti-notch2 antibodies and methods of use
EP2077325A4 (en)	2012-04-11	MONOCLONAL ANTIBODY AND ITS USE
EP2540742A4 (en)	2014-02-12	MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF